Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 8/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471278 | 0.86 | CNR2 (0.53) | PTGER2CNR2 | |
| SCHEMBL1471086 | 0.84 | PTGER2 (0.46) | PTGER2 | |
| SCHEMBL12749283 | 0.83 | CNR2 (0.46) | PTGER2CNR2 | |
| SCHEMBL1471097 | 0.82 | PTGER2 (0.49) | PTGER2LTB4R | |
| SCHEMBL1471605 | 0.80 | PTGER2 (0.43) | PTGER2CNR2LTB4R | |
| SCHEMBL5725576 | 0.80 | CNR2 (0.51) | PTGER2CNR2LTB4R | |
| SCHEMBL5725268 | 0.80 | PTGER2 (0.46) | PTGER2CNR2LTB4R | |
| SCHEMBL5046581 | 0.76 | PTGER2 (0.48) | PTGER2 | |
| SCHEMBL5046626 | 0.76 | PTGER2 (0.46) | PTGER2 | |
| SCHEMBL5050272 | 0.75 | TBXAS1 (0.53) | PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | claimed |
| US-7915316-B2 | Sulfonamides | ALLERGAN, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142471-A1 | SULFONAMIDES | CRYZ, QDPR, GLRX3 | PTGER2 1557/4885CNR2 160/4885LTB4R 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.